Genomics LIVE

 

Precision Medicine is going to be at the forefront of the next era of clinical treatment; and what is at the forefront of Precision Medicine?
Genomics.


Whether you are using it for drug development or diagnosis, there are still hurdles to overcome to effectively implement the next era of genomic medicine.


Join us at Genomics Live 2020 where we will be bringing together leaders from Pharma, Healthcare and Academia to share insights and improve efficiencies that will benefit patients worldwide.

 

Tracks

 
Liquid Biopsy   

The development of liquid biopsy technologies is an integral factor of a revolution in the diagnostic landscape, offering highly sensitive insights into patient diagnosis with minimally invasive, cost-efficient procedures. This track is designed to bring together leaders to discuss the technological challenges of liquid biopsies, CTCS, Exosomes, CtDNA, and Clinical Relevance of liquid biopsy in the clinic. 
 
Cancer Diagnostics & Precision Oncology 

One of the biggest areas where Genomics is making the biggest impact is in oncology. Cancer is affecting a growing number of the population, but being a genomic disease allows us to utilise genomics to diagnose and choose better treatment options.This track is designed for leaders to discuss how the use of genomics is revolutionising cancer treatment, diagnostics, patient stratification, and clinical implementation bedside. 

 
Single-Cell Analysis 

The examination of single cells is revolutionising our understanding of health cad disease. The technologies to isolate and analyse these cells are rapidly developing, showing new promise and expanding the applications. However, challenges in validation, interpretation and method standardisation remain before biomarker analysis from single cells can be integrated into diagnostic use.The single-cell analysis track will showcase single cell case studies for diagnostic and therapeutic applications and discuss the latest technological and data analysis challenges associated with this.
 
Cancer Epigenetics 

It is largely known that DNA methylation affects oncogenes. A better understanding of cancer epigenetics and discovering new targets for methylation activity has the potential transform oncology treatment in the near future. New for 2020, we are bringing together leaders in the study of epigenetics and highlight the latest developments for epigenetic targets. 
 


 

Digital Pathology & Tissue Diagnostics 

An integral step in the diagnostic process is pathological analysis. The digitalisation of this is rapidly advancing the diagnostic space, offering a more accurate and timely response to patients and aid in research.This track will showcase the latest in the development of Digital Pathology technologies, showcase how this can be of benefit to the key research that is driving industry and streamline hospital diagnostics. 

Novel Technologies & Clinical Biomarkers 

The success of patient-centric precision medicine relies on a solid predictive biomarker foundation. While drug developers fight for market share for similar drug targets, healthcare providers are looking for robust clinical benefit to patients. Luckily, advancements in the next generation of biomarkers is rapid and novel biomarker and genomic technologies are paving the way for this.  This track brings together leaders to showcase the latest case studies in the search for novel biomarkers, opportunities for growth and overcoming the challenges for biomarkers as therapeutic targets.
 

Immuno-oncology & Companion Diagnostics 

Progress in the immuno-oncology space is rapidly advancing cancer treatment, but there are still challenges in patient stratification and monitoring. Companion Diagnostics can offer insight into immunotherapy efficacy, safety and can expedite immunotherapies to the market. This track is designed to discuss the latest development of robust assays, overcoming commercialisation issues and showcase latest patient case studies.
 

Multi-omics & Precision Medicine 

Precision Medicine is not based purely on Genomics, now, we are focusing on more drug targets, namely “multi-omics”, or “X-Omics”.
Using a combination of omics offers a more comprehensive understanding of the disease and targets.This track offers a unique opportunity to highlight the use of multi-omics and personalised sequencing to improve patient care, and how this can be implemented routinely. 
 

DOWNLOAD PROSPECTUS
 

Contact us

To sponsor or exhibit contact:
Harry Ludbrook
+44 (0)207 092 1049

Harry.Ludbrook@terrapinn.com


To speak:
Chris Shanks
+44 (0)20 7092 1151

chris.shanks@terrapinn.com